Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2025)

Tango Therapeutics has reported Non-Current Assets over the past 6 years, most recently at $44.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $44.9 million for Q4 2025, down 10.4% from a year ago — trailing twelve months through Dec 2025 was $188.5 million (down 9.82% YoY), and the annual figure for FY2025 was $44.9 million, down 10.4%.
  • Non-Current Assets for Q4 2025 was $44.9 million at Tango Therapeutics, down from $46.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TNGX hit a ceiling of $166.8 million in Q2 2021 and a floor of $7.8 million in Q4 2021.
  • Median Non-Current Assets over the past 5 years was $52.3 million (2024), compared with a mean of $56.6 million.
  • Peak annual rise in Non-Current Assets hit 682.88% in 2022, while the deepest fall reached 93.48% in 2022.
  • Tango Therapeutics' Non-Current Assets stood at $7.8 million in 2021, then soared by 682.88% to $61.2 million in 2022, then decreased by 8.45% to $56.0 million in 2023, then decreased by 10.49% to $50.1 million in 2024, then decreased by 10.4% to $44.9 million in 2025.
  • The last three reported values for Non-Current Assets were $44.9 million (Q4 2025), $46.4 million (Q3 2025), and $47.8 million (Q2 2025) per Business Quant data.